Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort.

Dig Dis Sci · 2022 · PMC7942521 · PMID 33751325

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Similarly, refractoriness to anti-TNF treatment predicted lack of early response and also showed a strong trend toward lack of clinical remission at week 54.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.